Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Discovery: Overview01:26

Drug Discovery: Overview

11.1K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
11.1K
Allosteric Regulation01:08

Allosteric Regulation

63.0K
Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
63.0K
Ligand Binding and Linkage00:49

Ligand Binding and Linkage

5.5K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked.  In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
5.5K
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

16.6K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
16.6K
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:22

Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

2.0K
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
2.0K
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

4.0K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

High-Throughput Screening Identifies Small-Molecule Inhibitors of the Tau-LRP1 Interaction.

bioRxiv : the preprint server for biology·2026
Same author

Biased signaling at NTSR1 differentially regulates inhibitory synaptic transmission in the extended amygdala and suppresses motivated feeding in mice.

bioRxiv : the preprint server for biology·2026
Same author

Structure-guided discovery of non-catechol dopamine D1 receptor ligands with biased agonism and antagonism.

The Journal of biological chemistry·2026
Same author

Large Library Docking for Polypharmacology.

Journal of medicinal chemistry·2026
Same author

Electrical stimulation of the vagus nerve improves amyloid pathology in delirium superimposed on dementia.

Bioelectronic medicine·2026
Same author

Perinatal exposure to perfluoroalkyl substances impairs maternal care and induces depressive-like behavior in mice.

Toxicological sciences : an official journal of the Society of Toxicology·2025

Related Experiment Video

Updated: Jan 18, 2026

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

14.2K

Virtual Compound Screening for Discovery of Dopamine D1 Receptor Biased Allosteric Modulators.

Yang Zhou1, William C Wetsel2,3, Steven H Olson4

  • 1Department of Cell Biology, Duke University Medical Center, Durham, North Carolina 27710, United States.

Journal of Chemical Information and Modeling
|September 11, 2025
PubMed
Summary

Researchers developed a new drug screening platform to find safer dopamine D1 receptor (D1R) therapies for Parkinson's disease (PD). They identified a lead compound, DUSBI-A3, that selectively targets D1R, offering potential for improved PD treatment with fewer side effects.

More Related Videos

Parallel Interrogation of β-Arrestin2 Recruitment for Ligand Screening on a GPCR-Wide Scale using PRESTO-Tango Assay
09:03

Parallel Interrogation of β-Arrestin2 Recruitment for Ligand Screening on a GPCR-Wide Scale using PRESTO-Tango Assay

Published on: March 10, 2020

13.7K
A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

9.4K

Related Experiment Videos

Last Updated: Jan 18, 2026

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

14.2K
Parallel Interrogation of β-Arrestin2 Recruitment for Ligand Screening on a GPCR-Wide Scale using PRESTO-Tango Assay
09:03

Parallel Interrogation of β-Arrestin2 Recruitment for Ligand Screening on a GPCR-Wide Scale using PRESTO-Tango Assay

Published on: March 10, 2020

13.7K
A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

9.4K

Area of Science:

  • Neuropharmacology
  • Drug Discovery
  • Molecular Biology

Background:

  • The dopamine D1 receptor (D1R) is a key target for central nervous system disorders like Parkinson's disease (PD).
  • Current PD therapies, such as L-DOPA, have significant side effects due to off-target activities.
  • Functional selectivity in G-protein and β-arrestin signaling presents opportunities for developing safer D1R modulators.

Purpose of the Study:

  • To identify novel allosteric compounds targeting the D1R intracellular loop 2 (ICL2).
  • To develop D1R-selective biased agonists or antagonists with improved therapeutic profiles for PD.

Main Methods:

  • Designed a computational drug-screening platform to analyze large virtual chemical libraries.
  • Screened for compounds that modulate D1R-mediated G-protein and β-arrestin signaling pathways.
  • Assessed the selectivity of identified compounds across different dopamine receptor subtypes.

Main Results:

  • Identified two distinct allosteric compounds that enhance D1R-mediated β-arrestin recruitment and inhibit G-protein activation.
  • The lead candidate, DUSBI-A3, demonstrated high selectivity for D1R over related dopamine receptors via β-arrestin activation.
  • These findings validate the strategy of pursuing D1R-selective, biased ligands.

Conclusions:

  • A novel drug-screening approach successfully identified selective D1R allosteric modulators.
  • DUSBI-A3 represents a promising lead compound for developing next-generation PD therapies with reduced side effects.
  • Targeting D1R functional selectivity offers a viable strategy for safer and more effective CNS disorder treatments.